Kala Bio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 43

Employees

  • Stock Symbol
  • KALA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $10.73
  • (As of Thursday Closing)

Kala Bio General Information

Description

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Contact Information

Website
www.kalarx.com
Formerly Known As
Hanes Newco, KalaPharmaceuticals, Kala Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1167 Massachusetts Avenue
  • Arlington, MA 02476
  • United States
+1 (781)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Nanotechnology, TMT, Life Sciences
Corporate Office
  • 1167 Massachusetts Avenue
  • Arlington, MA 02476
  • United States
+1 (781)

Kala Bio Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kala Bio Stock Performance

As of 06-Feb-2025, Kala Bio’s stock price is $10.73. Its current market cap is $65.4M with 6.09M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.73 $9.70 $4.21 - $10.79 $65.4M 6.09M 48.2K -$11.86

Kala Bio Financials Summary

As of 30-Sep-2024, Kala Bio has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 8,867 (1,129) 51,139 61,787
Revenue 0 0 3,892 11,240
EBITDA (35,032) (38,793) (37,683) (133,354)
Net Income (38,963) (42,199) (44,822) (142,605)
Total Assets 54,079 55,949 86,820 139,427
Total Debt 37,039 36,323 42,950 80,188
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kala Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kala Bio‘s full profile, request access.

Request a free trial

Kala Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kala Bio‘s full profile, request access.

Request a free trial

Kala Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to rese
Biotechnology
Arlington, MA
43 As of 2023

Lexington, MA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kala Bio Competitors (28)

One of Kala Bio’s 28 competitors is Aldeyra Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
PulseSight Therapeutics Venture Capital-Backed Paris, France
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Exonate Venture Capital-Backed Cambridge, United Kingdom
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
You’re viewing 5 of 28 competitors. Get the full list »

Kala Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kala Bio Acquisitions (1)

Kala Bio’s most recent deal was a Merger/Acquisition with Combangio for . The deal was made on 15-Nov-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Combangio 15-Nov-2021 Merger/Acquisition Drug Discovery
To view Kala Bio’s complete acquisitions history, request access »

Kala Bio ESG

Risk Overview

Risk Rating

Updated October, 04, 2022

35.77 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,638

Rank

Percentile

Pharmaceuticals

Industry

of 1,008

Rank

Percentile

Pharmaceuticals

Subindustry

of 473

Rank

Percentile

To view Kala Bio’s complete esg history, request access »

Kala Bio FAQs

  • When was Kala Bio founded?

    Kala Bio was founded in 2009.

  • Where is Kala Bio headquartered?

    Kala Bio is headquartered in Arlington, MA.

  • What is the size of Kala Bio?

    Kala Bio has 43 total employees.

  • What industry is Kala Bio in?

    Kala Bio’s primary industry is Biotechnology.

  • Is Kala Bio a private or public company?

    Kala Bio is a Public company.

  • What is Kala Bio’s stock symbol?

    The ticker symbol for Kala Bio is KALA.

  • What is the current stock price of Kala Bio?

    As of 06-Feb-2025 the stock price of Kala Bio is $10.73.

  • What is the current market cap of Kala Bio?

    The current market capitalization of Kala Bio is $65.4M.

  • Who are Kala Bio’s competitors?

    Aldeyra Therapeutics, PulseSight Therapeutics, ONL Therapeutics, Exonate, and Alnylam Pharmaceuticals are some of the 28 competitors of Kala Bio.

  • What is Kala Bio’s annual earnings per share (EPS)?

    Kala Bio’s EPS for 12 months was -$11.86.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »